ViroGates AS (OCSE:VIRO) Ending Cash Position: kr22.28 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:VIRO ViroGates AS OCSE:VIRO
43 GF Score
Price kr10.90
GF Value kr6.58
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Ending Cash Position?

ViroGates AS OCSE:VIRO 43 Ending Cash Position is kr22.28 Mil as of Mar. 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 43/100 and a GF Value™ of kr6.58 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ViroGates AS's Ending Cash Position for the quarter that ended in Mar. 2026 was kr22.28 Mil.

ViroGates AS's quarterly Ending Cash Position increased from Sep. 2025 (kr9.12 Mil) to Dec. 2025 (kr26.30 Mil) but then declined from Dec. 2025 (kr26.30 Mil) to Mar. 2026 (kr22.28 Mil).

ViroGates AS's annual Ending Cash Position declined from Dec. 2023 (kr16.03 Mil) to Dec. 2024 (kr12.21 Mil) but then increased from Dec. 2024 (kr12.21 Mil) to Dec. 2025 (kr26.30 Mil).

ViroGates AS Ending Cash Position Related Terms

ViroGates AS Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ViroGates AS's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS Ending Cash Position Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.86 9.88 16.03 12.21 26.30

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.23 11.88 9.12 26.30 22.28
OCSE:VIRO
43GF Score
ViroGates AS OCSE:VIRO
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ViroGates AS Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ViroGates AS's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=12.208+14.089
=26.30

ViroGates AS's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=26.297+-4.017
=22.28

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of kr22.28 Mil mean?
ViroGates AS (OCSE:VIRO) has a Ending Cash Position of kr22.28 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ViroGates AS and its competitors.
Is ViroGates AS's Ending Cash Position too high?
ViroGates AS's current Ending Cash Position is kr22.28 Mil. Overall, ViroGates AS has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Ending Cash Position compare to ABT and SYK?
ViroGates AS's Ending Cash Position of kr22.28 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ViroGates AS and its competitors. ViroGates AS's current Ending Cash Position is kr22.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.58, compared to a current price of kr10.90 — trading 65.7% above its estimated fair value. The current Ending Cash Position is kr22.28 Mil. ViroGates AS's overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Ending Cash Position is kr22.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of kr10.90 is trading 65.7% above its estimated GF Value™ of kr6.58. GuruFocus considers ViroGates AS to be Significantly Overvalued.

Key valuation signals for OCSE:VIRO:

  • Ending Cash Position: kr22.28 Mil
  • GF Value™: kr6.58 vs. price of kr10.90 (65.7% above fair value)
  • GF Score™: 43/100 with 2 warning signs

No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ViroGates AS Business Description

Other Exchanges EP2:Germany
Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
43GF Score

Get the complete analysis for OCSE:VIRO

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.90
Price
kr6.58
GF Value